Methylphenaxiro

Methylphenidate, the active ingredient in Methylphenaxiro, is a central nervous system stimulant presented as an oral tablet for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy in children, adolescents, adults, including elderly patients.

GNH USA supplies Methylphenaxiro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from comprehensive regulatory support and consistent product availability across multiple markets.

Methylphenidate acts on central nervous system pathways involved in attention and wakefulness, and is used for the following conditions:

Attention deficit hyperactivity disorder (ADHD): Improves concentration, reduces hyperactivity and impulsivity in children, adolescents, and adults. Narcolepsy: Decreases excessive daytime sleepiness and improves wakefulness.

Methylphenidate may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Loss of appetite: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach pain: abdominal discomfort or cramps. - Nausea: feeling of sickness or urge to vomit. - Increased heart rate: mild tachycardia.

Serious or Rare Side Effects: - Psychotic symptoms: hallucinations or delusional thoughts. - Severe hypertension: markedly elevated blood pressure. - Cardiac arrhythmia: irregular heart rhythm. - Peripheral vasculitis: inflammation of blood vessels. - Allergic reaction: rash, swelling, or anaphylaxis.

Before prescribing Methylphenidate, clinicians should consider several safety precautions to minimize risks.

Cardiovascular assessment: evaluate heart rate, blood pressure, and history of cardiac disease. Psychiatric evaluation: monitor for anxiety, agitation, or emerging psychosis. Growth monitoring: track height and weight in children during long‑term therapy. Drug abuse potential: assess risk of misuse or dependence. Concomitant MAO inhibitor use: avoid within 14 days of stopping an MAOI. Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Methylphenidate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: may increase cardiovascular side effects. - Antihypertensive agents: can reduce blood pressure control.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may increase serotonin levels. - Anticonvulsants (e.g., carbamazepine): may reduce methylphenidate plasma concentrations. - CYP2D6 inhibitors (e.g., fluoxetine): may raise methylphenidate levels.